Terns Pharmaceuticals (NASDAQ:TERN) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Terns Pharmaceuticals (NASDAQ:TERN) to a sell rating in a report published on Saturday.

Several other analysts have also issued reports on the company. Mizuho set a $53.00 price target on Terns Pharmaceuticals in a report on Friday, March 27th. Oppenheimer reaffirmed a “market perform” rating and issued a $58.00 price objective on shares of Terns Pharmaceuticals in a research note on Monday, April 27th. BMO Capital Markets lowered Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Friday, March 27th. Finally, Leerink Partners lowered Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $55.14.

Terns Pharmaceuticals Stock Performance

NASDAQ:TERN opened at $52.95 on Friday. The stock has a 50-day simple moving average of $49.68 and a two-hundred day simple moving average of $37.90. Terns Pharmaceuticals has a 52-week low of $2.65 and a 52-week high of $53.19. The firm has a market capitalization of $6.12 billion, a PE ratio of -51.41 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.06. Equities analysts forecast that Terns Pharmaceuticals will post -1.22 earnings per share for the current fiscal year.

Insider Transactions at Terns Pharmaceuticals

In related news, CEO Amy L. Burroughs sold 14,583 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the transaction, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Emil Kuriakose sold 942 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total value of $49,690.50. Following the transaction, the insider directly owned 105,673 shares of the company’s stock, valued at approximately $5,574,250.75. The trade was a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 30,108 shares of company stock valued at $1,302,370. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Terns Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd raised its position in Terns Pharmaceuticals by 237.2% during the third quarter. Dynamic Technology Lab Private Ltd now owns 66,576 shares of the company’s stock valued at $500,000 after purchasing an additional 46,831 shares during the period. SG Americas Securities LLC purchased a new stake in Terns Pharmaceuticals during the fourth quarter valued at approximately $1,772,000. AlphaQuest LLC raised its position in Terns Pharmaceuticals by 9,088,200.0% during the third quarter. AlphaQuest LLC now owns 90,883 shares of the company’s stock valued at $683,000 after purchasing an additional 90,882 shares during the period. JPMorgan Chase & Co. raised its position in Terns Pharmaceuticals by 90.6% during the third quarter. JPMorgan Chase & Co. now owns 682,708 shares of the company’s stock valued at $5,127,000 after purchasing an additional 324,502 shares during the period. Finally, Capricorn Fund Managers Ltd purchased a new stake in Terns Pharmaceuticals during the fourth quarter valued at approximately $6,118,000. 98.26% of the stock is owned by institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.